Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
6 pending office actions • 5 art units • 6 examiners • 0 of 6 (0%) have an AI response strategy ready • 5 patents granted in the last 365 days
Janux Therapeutics Inc. currently has 4 pending office actions in the Biotechnology & Pharmaceuticals technology area. These matters are distributed among 4 distinct examiners and 3 distinct art units. SAOUD, CHRISTINE J is the busiest examiner for the portfolio, currently managing 1 pending office action. With 4 pending office actions total and 4 distinct examiners, the company's prosecution is spread across multiple points of contact.
The use of 3 distinct art units indicates that the company's biotechnology research spans several specialized sub-fields. Because SAOUD, CHRISTINE J is the busiest examiner with only 1 pending office action, the applicant must manage four separate examiner relationships simultaneously to advance its current portfolio. This distribution suggests that the company's intellectual property strategy involves navigating a variety of examiner perspectives within a relatively small number of art units. Practitioners must ensure that technical arguments remain consistent across the 3 distinct art units to maintain a cohesive patent landscape. Successfully managing these diverse interactions will be essential for the company's overall success in the Biotechnology & Pharmaceuticals sector. This decentralized approach requires careful coordination to ensure that all pending matters reach a favorable conclusion while addressing the specific nuances of each individual examiner's feedback.
Based on the USPTO statutory response window for each pending office action. 4 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 4 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (17%) |
| §112 only | 2 (33%) |
| Double-patenting only | 1 (17%) |
| Double-patenting + other | 1 (17%) |
| Multi-statute (no §101) | 1 (17%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SAOUD, CHRISTINE J | 1 | 58.0% | +37.2% |
| LEE, YIE CHIA | 1 | 69.2% | +46.6% |
| CUNNINGCHEN, KATHLEEN MARY | 1 | 61.1% | +62.5% |
| FAUST, AMBER KATHLEEN | 1 | 60.6% | +53.3% |
| TAYLOR, LIA ELAN | 1 | 64.4% | +29.4% |
| SHUPE, ELIZABETH A | 1 | 66.2% | +44.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18249886 | MULTISPECIFIC ANTIBODIES FOR TARGETING CD28 AND PD-L1 AND METHODS OF USE THEREOF | TAYLOR, LIA ELAN | 33d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 6 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18314077 | COMPOSITIONS AND METHODS RELATED TO TUMOR ACTIVATED ANTIBODIES TARGETING PSMA AND EFFECTOR CELL ANTIGENS | CUNNINGCHEN, KATHLEEN MARY | 38d overdue |
| 18256276 | HALF-LIFE EXTENDING COMPOSITIONS AND METHODS | SAOUD, CHRISTINE J | 37d overdue |
| 18249886 | MULTISPECIFIC ANTIBODIES FOR TARGETING CD28 AND PD-L1 AND METHODS OF USE THEREOF | TAYLOR, LIA ELAN | 33d |
| 18249879 | ANTIBODIES TARGETING HER2 AND CD3 AND USES THEREOF | FAUST, AMBER KATHLEEN | 61d |
| 18314090 | TUMOR ACTIVATED MULTISPECIFIC ANTIBODIES FOR TARGETING CD28 AND PD-L1 AND METHODS OF USE THEREOF | LEE, YIE CHIA | — |
| 17616278 | TUMOR ACTIVATED T CELL ENGAGERS AND METHODS OF USE THEREOF | SHUPE, ELIZABETH A | — |
| Art Unit | Apps |
|---|---|
| 1643 | 2 |
| 1645 | 1 |
| 1642 | 1 |
| 1646 | 1 |
| 1641 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18256276 | HALF-LIFE EXTENDING COMPOSITIONS AND METHODS | SAOUD, CHRISTINE J | 1645 | DP | Final Rejection | 37d overdue | Pending | Jun 07, 2023 |
| 18314090 | TUMOR ACTIVATED MULTISPECIFIC ANTIBODIES FOR TARGETING CD28 AND PD-L1 AND METHODS OF USE THEREOF | LEE, YIE CHIA | 1642 | §112Other | Non-Final OA | — | Pending | May 08, 2023 |
| 18314077 | COMPOSITIONS AND METHODS RELATED TO TUMOR ACTIVATED ANTIBODIES TARGETING PSMA AND EFFECTOR CELL ANTIGENS | CUNNINGCHEN, KATHLEEN MARY | 1646 | §112Other | Final Rejection | 38d overdue | Pending | May 08, 2023 |
| 18249879 | ANTIBODIES TARGETING HER2 AND CD3 AND USES THEREOF | FAUST, AMBER KATHLEEN | 1643 | §103DPOther | Final Rejection | 61d | Pending | Apr 20, 2023 |
| 18249886 | MULTISPECIFIC ANTIBODIES FOR TARGETING CD28 AND PD-L1 AND METHODS OF USE THEREOF | TAYLOR, LIA ELAN | 1641 | §103§112 | Final Rejection | 33d | Pending | Apr 20, 2023 |
| 17616278 | TUMOR ACTIVATED T CELL ENGAGERS AND METHODS OF USE THEREOF | SHUPE, ELIZABETH A | 1643 | §103Other | Non-Final OA | — | Pending | Dec 03, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial